AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Cdk5-Specific Inhibitory Peptides

Summary
Cyclin-dependent kinases (Cdks) are key regulatory enzymes in the eukaryotic cell cycle. The activation of a Cdk depends on its association with its specific cyclin partner. The activity of these enzymes is further regulated by an intricate system of protein-protein interactions and phosphorylation. Cdk5 activity has been observed only in neuronal and in developing muscle cells. Experimental evidence has demonstrated that Cdk5 plays important role in neurite outgrowth, patterning of cortex and cerebellum, and cytoskeletal dynamics. Loss of regulation of Cdk5 has been considered to be involved in Alzheimer' s disease. However, all currently known peptides that have regulatory effects on Cdk5 and Cdk2 are usually Adenosine Tri-Phosphate (ATP) / Adenosine Di-Phosphate (ADP)-based and low efficiency and specificity of their binding are the disadvantages.

The invention provides new potent Cdk5/Cdk2 specific inhibitory peptides. In the case of Cdk5, its activation has been shown to occur upon the binding of neuronal Cdk5 activator (Nck5a). The novel Cdk inhibitory peptide is derived from an internal fragment of Nck5a. This peptide is able to bind to and hence inhibit the Cdk5/Nck5a and Cdk2/cyclinA complex. The peptide possesses important and valuable implications as a scientific tool to support biomedical research in cell cycle regulation, and can be developed into potential drugs targeting Cdk5/Cdk2 inactivation for Alzheimer' s disease.
Technology Benefits
1. High potency
2. High stability
3. High specificity
Technology Application
- Drugs for Alzheimer' s disease
- Bio-medical research tools
- Cell cycle regulation
Supplementary Information
Patent Number: US6693166B1
Application Number: US1999289612A
Inventor: Wang, Jerry H. | Zhang, Mingjie | Tang, Damu
Priority Date: 12 Apr 1999
Priority Number: US6693166B1
Application Date: 12 Apr 1999
Publication Date: 17 Feb 2004
IPC Current: A61K003800 | A61K003817
US Class: 530324 | 530326 | 530350 | 514002 | 514012 | 514013
Assignee Applicant: The Hong Kong University of Science & Technology
Title: Cdk5-specific inhibitory peptides | Cdk5--specific inhibitory peptides
Usefulness: Cdk5-specific inhibitory peptides | Cdk5--specific inhibitory peptides
Summary: The inhibitory peptide is useful as a tool in biomedical research.
Novelty: New inhibitory peptide derived from a neuronal-derived cyclin-dependent kinase 5 activator (Nck5a) for the activation of the cyclin-dependent-kinase 5 (Cdk5), useful as a tool in biomedical research
Industry
Biomedical
Sub Category
DNA/Gene Engineering
Application Date
12 Apr 1999
Application No.
US 09/289612
Patent Information
US 6693166
ID No.
TTC.PA.077
Country/Region
Hong Kong

For more information, please click Here
Mobile Device